Business Wire

Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative ...

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Positive topline results from the TROPION-Breast01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically ...
Business Wire

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan ...
The American Journal of Managed Care

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

Datopotamab deruxtecan-dlnk received FDA accelerated approval for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response ...
Nasdaq

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials “Acquired resistance to front-line therapies and, ultimately, ...
Nasdaq

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and ...

Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan showed a 42.7% objective response rate in previously treated patients Data support recent BLA submission in the U.S. for this patient population ...
PharmiWeb

Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer

Parallel applications based on TROPION-Lung01 and TROPION-Breast01 Phase III trial results demonstrating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan significantly improved progression-free ...
ascopubs.org

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast ...

Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS) Adult ...
Healio

Datopotamab deruxtecan extends PFS in advanced breast cancer

Please provide your email address to receive an email when new articles are posted on . Datopotamab deruxtecan significantly improved PFS compared with chemotherapy in patients with previously treated ...
Monthly Prescribing Reference

FDA Grants Priority Review to Datopotamab Deruxtecan for Metastatic TNBC

Datopotamab deruxtecan significantly improves overall survival compared with chemotherapy in previously untreated metastatic TNBC. The Food and Drug Administration (FDA) has accepted for Priority ...
ascopubs.org

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate ...
The American Journal of Managed Care

Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% lacking actionable PD-L1 eligibility and historically limited to ...
PharmiWeb

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative ...

Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the ...